These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 30541374)

  • 1. Rapamycin, proliferation and geroconversion to senescence.
    Blagosklonny MV
    Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK drives cyclin D1 hyperelevation during geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.
    Leontieva OV; Blagosklonny MV
    Oncotarget; 2014 Dec; 5(24):12715-27. PubMed ID: 25587030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.
    Blagosklonny MV
    Aging (Albany NY); 2012 Mar; 4(3):159-65. PubMed ID: 22394614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.
    Wang R; Yu Z; Sunchu B; Shoaf J; Dang I; Zhao S; Caples K; Bradley L; Beaver LM; Ho E; Löhr CV; Perez VI
    Aging Cell; 2017 Jun; 16(3):564-574. PubMed ID: 28371119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell senescence, rapamycin and hyperfunction theory of aging.
    Blagosklonny MV
    Cell Cycle; 2022 Jul; 21(14):1456-1467. PubMed ID: 35358003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia suppresses conversion from proliferative arrest to cellular senescence.
    Leontieva OV; Natarajan V; Demidenko ZN; Burdelya LG; Gudkov AV; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13314-8. PubMed ID: 22847439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gerosuppression in confluent cells.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2014 Dec; 6(12):1010-8. PubMed ID: 25585637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia and gerosuppression: the mTOR saga continues.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2012 Nov; 11(21):3926-31. PubMed ID: 22987149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gerosuppression by pan-mTOR inhibitors.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2016 Dec; 8(12):3535-3551. PubMed ID: 28077803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
    Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
    J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S6K in geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2013 Oct; 12(20):3249-52. PubMed ID: 24036549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors.
    Blagosklonny MV
    Cell Cycle; 2011 Jul; 10(14):2295-8. PubMed ID: 21715978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107.
    Khor ES; Wong PF
    Int J Biochem Cell Biol; 2018 Aug; 101():64-73. PubMed ID: 29857052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin decelerates cellular senescence.
    Demidenko ZN; Zubova SG; Bukreeva EI; Pospelov VA; Pospelova TV; Blagosklonny MV
    Cell Cycle; 2009 Jun; 8(12):1888-95. PubMed ID: 19471117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth stimulation leads to cellular senescence when the cell cycle is blocked.
    Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2008 Nov; 7(21):3355-61. PubMed ID: 18948731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential.
    Demidenko ZN; Blagosklonny MV
    Aging (Albany NY); 2009 Dec; 1(12):1008-16. PubMed ID: 20157583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.